SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)

CAPS Rating: 3 out of 5

A biopharmaceutical company, which is engaged in the development and commercialization of novel therapeutics to treat life-threatening diseases.

Recs

0
Player Avatar wahookiller (< 20) Submitted: 2/14/2007 12:30:15 AM : Outperform Start Price: $2.87 SCLN Score: +104.22

Putting a quality sells team in place in China to market it current product. This will allow them to expand on their already successful Zaxadin medication and they will be in place for their new products and could possibly market other newly approved meds.

Featured Broker Partners


Advertisement